Four states dropped coverage in late 2025: California, New Hampshire, Pennsylvania , and South Carolina all eliminated Medicaid coverage of GLP-1s for obesity treatment reducing the national count from 16 states to 13
Clinical trials show body weight reductions that surpass anything weve seen from current GLP-1 medications
This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
Company background Ro is the older company, founded in 2017, and has grown into a broad telehealth brand spanning multiple conditions
Ginger tea, plain crackers, and a slow morning are old tricks that still work
When Novo Nordisk faced production issues, choosing Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became easier
